GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JW Life Science Corp (XKRX:234080) » Definitions » Cash-to-Debt

JW Life Science (XKRX:234080) Cash-to-Debt : 0.61 (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is JW Life Science Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. JW Life Science's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.61.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, JW Life Science couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for JW Life Science's Cash-to-Debt or its related term are showing as below:

XKRX:234080' s Cash-to-Debt Range Over the Past 10 Years
Min: 0   Med: 0.09   Max: 0.61
Current: 0.61

During the past 13 years, JW Life Science's highest Cash to Debt Ratio was 0.61. The lowest was 0.00. And the median was 0.09.

XKRX:234080's Cash-to-Debt is ranked worse than
58.41% of 1046 companies
in the Drug Manufacturers industry
Industry Median: 0.95 vs XKRX:234080: 0.61

JW Life Science Cash-to-Debt Historical Data

The historical data trend for JW Life Science's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

JW Life Science Cash-to-Debt Chart

JW Life Science Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.07 0.11 0.43 0.61

JW Life Science Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.78 0.63 0.48 0.61

Competitive Comparison of JW Life Science's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, JW Life Science's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JW Life Science's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, JW Life Science's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where JW Life Science's Cash-to-Debt falls into.



JW Life Science Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

JW Life Science's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

JW Life Science's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


JW Life Science  (XKRX:234080) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


JW Life Science Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of JW Life Science's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


JW Life Science (XKRX:234080) Business Description

Traded in Other Exchanges
N/A
Address
28, Hanjin 1-gil, Songak-eup, Dangjin-si, Chungcheongnam-do, Seoul, KOR, 343-823
JW Life Science Corp develops and produces infusion solutions. Its products contents amino acids, lipids, proteins, vitamins, and minerals to patients.

JW Life Science (XKRX:234080) Headlines

No Headlines